Recovery peptides

TB-500

A synthetic fragment associated with thymosin beta-4 biology, with evidence often extrapolated from the parent molecule.

Thymosin beta-4 fragmentFequesetideAc-LKKTETQ

Concise answer

What is TB-500?

TB-500 is commonly discussed as a thymosin beta-4 fragment. Most clinical evidence belongs to full-length thymosin beta-4, not the consumer-marketed fragment.

Definition

What It Is

TB-500 is marketed as a synthetic peptide fragment related to thymosin beta-4, a naturally occurring actin-binding protein involved in cell migration and wound biology.

Status

Legal and Regulatory Notes

FDA: Not FDA-approved as a medication for human use.
Research: The strongest mechanistic literature concerns full-length thymosin beta-4. TB-500 fragment evidence is thinner and should not be treated as equivalent.
Sport: Thymosin beta-4 related compounds and growth-factor pathways create anti-doping risk. Tested athletes should consult WADA, USADA, and sport-specific rules.

Research map

How TB-500 Is Being Studied

Cell migration and actin-related signalingCorneal, dermal, and cardiac repair models involving thymosin beta-4Differences between full-length thymosin beta-4 and smaller fragmentsDetection and anti-doping concerns

People

Human Research

Human research is limited and often involves full-length thymosin beta-4 preparations, not necessarily TB-500 as sold in research-peptide markets.

Models

Animal and Cell Research

Preclinical work supports biologic plausibility for thymosin beta-4 pathways, but fragment-specific translation remains uncertain.

Safety

Known Risks and Side Effects

Unknown fragment-specific human safety profile
Theoretical concerns around angiogenesis in inappropriate contexts
Product identity confusion between TB-500 fragment and full-length thymosin beta-4
Anti-doping and unapproved-drug risks

Compliance

Interpretation Guardrails

Full-length thymosin beta-4 research should not be automatically applied to TB-500 products.
No sourcing or use recommendations are provided by PeptideWars.
Discuss wound, injury, or surgery questions with a licensed clinician.

Internal links

Related Battles and Profiles

Battle BPC-157 vs TB-500 Two recovery peptides with big online reputations and weak human outcome evidence. Profile BPC-157 A synthetic 15-amino-acid research peptide with extensive animal data and very limited human evidence. Profile GHK-Cu A copper-binding tripeptide discussed in skin biology, cosmetic formulations, and wound-healing research. Profile Sermorelin A GHRH analog historically studied for growth hormone deficiency testing and pediatric growth contexts. Guide Recovery Peptides A sober look at BPC-157, TB-500, and wound-healing claims without injury-cure hype. Guide Research-Only Peptides How to spot compounds where marketing has outrun human evidence and regulatory approval.

FAQ

Common Questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is commonly described as a fragment related to thymosin beta-4, while much of the published research is on the full-length molecule.

Is TB-500 FDA-approved?

No. PeptideWars classifies TB-500 as research-only and not FDA-approved for human use.

Which has better evidence, TB-500 or BPC-157?

Neither has strong human outcome evidence. TB-500 benefits are often extrapolated from thymosin beta-4 research, while BPC-157 is mostly animal-model research.

Sources

Citations and Official References

Editorial Review

Written by the PeptideWars Editorial Team. Medical reviewer placeholder: licensed clinician review should be completed before production launch. Last updated May 6, 2026.